James K Godfrey

12PUBLICATIONS
61CO-AUTHORS
Molecular targetsGene expression (incl. microarray and other genome-wide approaches)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 22, 2026
Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas.

|Sep 09, 2026
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.

|Oct 08, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.

Lei Gao, Avyakta Kallam, Geoffrey Shouse

|Jul 28, 2025
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.

Kirk Cahill, James Godfrey, Chadi Nabhan

|Jan 27, 2025
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.

Sravya Tumuluru, James K Godfrey, Alan Cooper

|Mar 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.

James K Godfrey, Lei Gao, Geoffrey Shouse

Pageof 2

Frequent Collaborators

5 joint publications

Sonali M Smith

5 joint publications

Alan Cooper

5 joint publications

Alex F Herrera

4 joint publications

Sravya Tumuluru